In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates

Mycoses

Volumn 49, Issue 3, 2006, Pages 220-225

  Alves, S H ^a,d   Da Matta, D A ^b   Azevedo, A C ^b   Loreto, E S ^a   Boff, E ^a   Santurio, J M ^a   Guarro, J ^c  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d NONE   (Brazil)

Author keywords

Albaconazole; Azoles; Candida species; Ravuconazole; Resistance

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NEW DRUG; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BRAZIL; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; ISSATCHENKIA ORIENTALIS;

EID: 33646254406     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01226.x     Document Type: Article

References (23)

1. Clemons KV Martinez M Calderon L Stevens DA Efficacy of ravuconazole in treatment of systemic murine histoplasmosis Antimicrob Agents Chemother 2002 46 922 4
2. Collin B Clancy CJ Nguyen MH Antifungal resistance in non-albicans Candida species Drug Resist Updat 1999 2 9 14
3. National Committee for Clinical laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2 Wayne, PA National Committee for Clinical Laboratory Standards 2002
4. Fung-Tomc JC Huczko E Minassian B Bonner D In vitro activity of a new oral triazole, BMS-207147 (ER-30346) Antimicrob Agents Chemother 1998 42 313 8
5. Yamazumi T Pfaller MA Messer SA Hosuton A Hollis RJ Jones RN In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans Antimicrob Agents Chemother 2000 44 2883 6
6. Diekema DJ Pfaller MA Messer SA et al. In vitro activities of BMS0207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in north and Latin America Antimicrob Agents Chemother 1999 43 2236 9
7. Capilla J Ortodena M Pastor FJ Guarro J In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi Antimicrob Agents Chemother 2001 45 2635 7
8. Ramos G Cuenca-Estrella M Monzón A Rodríguez-Tudela JL In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp J Antimicrob Chemother 1999 44 283 6
9. Pfaller MA Diekema DJ Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumugatus J Clin Microbiol 2004 42 4419 31
10. Pfaller MA Diekema DJ Messer SA Boyken L Hollis RJ Jones RN In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents Diagn Microbiol Infect Dis 2004 48 101 5
11. Pfaller MA Messer SA Hollis RJ Jones RN Diekema DJ In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp J Clin Microbiol 2002 46 1723 7
12. Pfaller MA Messer SA Boyken L Tendolkar S Hollis RJ Diekema DJ Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12 796 clinical isolates of Candida spp J Clin Microbiol 2204 42 3137 41
13. Nucci M Colombo AL Emergence of resistant Candida in neutropenic patients Braz J Infect Dis 2002 6 124 8
14. Pfaller MA Messer SA Boyken L Tendolkar S Hollis RJ Diekema DJ Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002 J Clin Microbiol 2002 42 3142 6
15. Barchiesi F Colombo AL McGough DA Fothergill AW Rinaldi MG In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus Antimicrob Agents Chemother 1994 38 1530 3
16. Cuenca-Estrella M Gomez-Lopez A Mellado E Garcia-Effron G Rodríguez-Tudela JL In vitro activities of ravuconazole and tour other antifungal agents against fluconazole-resistant or-susceptible clinical yeast isolates Antimicrob Agents Chemother 2004 48 3107 11
17. Bartroli J Turmo E Algueró M et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones J Med Chem 1998 41 1869 82
18. Ruhnke M Schmidt-Westhausen A Morschnäuser J Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in patients with AIDS J Antimicrob Chemother 2000 46 291 5
19. Milán EP Laet Sant'Anna P Melo ASA et al. Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients Diagn Microbiol Infect Dis 2001 41 29 35
20. Brandt ME Harrinson LH Pass M et al. Candida dubliniensis fungemia: the first four cases in North America Emerg Infect Dis 2000 6 46 9
21. Kirkpatrick WR Revankar SG McAtee RK et al. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing J Clin Microbiol 1998 36 3007 12
22. Marriott D Laxton M Harkness J Candida dubliniensis candidemia in Australia Emerg Infect Dis 2001 7 479
23. Meis JFGM Ruhnke M De Pauw BE Odds FC Siegert W Verweij PE Candida dubliniensis candidemia in patients with chemotherapy- induced neutropenia and bone marrow transplantation Emerg Infect Dis 1999 5 150 3